ReviewWorld journal of gastroenterology2016
Metastatic gastric cancer treatment: Second line and beyond.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 63 citations in OpenAlex.
- Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Targeting the c-Met/VEGFR Pathway to BoostCells · 2026Article
- Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study.Frontiers in immunology · 2025Article
- Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for Gastric Cancer.Journal of translational medicine · 2024Article
- Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.International journal of molecular sciences · 2024Review
- Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1α-FBLN5 signaling pathway.British journal of cancer · 2023Article
- Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.Biomedicines · 2023Review
- HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.International journal of molecular sciences · 2023Review
- Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer.Scientific reports · 2023Article
- Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models.Frontiers in oncology · 2023Article
- Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.Molecular cancer therapeutics · 2022Article
- Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors.European geriatric medicine · 2022Observational
- 5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone up-regulates miR-145 expression and inhibits proliferation of gastric cancer cells.Archives of medical science : AMS · 2022Article
- Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy.Annals of translational medicine · 2021Article
- Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.International journal of molecular sciences · 2021Article
- Loss of DAB2IP Contributes to Cell Proliferation and Cisplatin Resistance in Gastric Cancer.OncoTargets and therapy · 2021Article
- Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17.Oncology letters · 2019Article
- Effect of miR‑145 on gastric cancer cells.Molecular medicine reports · 2019Article
- Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- MAGI1 inhibits migration and invasion via blocking MAPK/ERK signaling pathway in gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced gastric cancer (aGC), not amenable to curative surgery, is still a burdensome illness tormenting afflicted patients and their healthcare providers. Whereas combination chemotherapy has been shown to improve survival and tumor related symptoms in the frontline setting, second-line therapy (SLT) is subject to much debate in the scientific community, mainly because of the debilitating effects of GC, which would impede the administration of cytotoxic therapy. Recent data has provided sufficient evidence for the safe use of SLT in patients with an adequate performance status. Taxanes, Irinotecan and even some Fluoropyrimidine analogs were found to provide a survival advantage in this subset of patients. Most importantly, quality of life measures were also improved through the use of adequate therapy. Even more pertinent were the findings involving antiangiogenic agents, which would add measurable improvements without significantly jeopardizing the patients' well-being. Further lines of therapy are cause for much more debate nowadays, but specific targeted agents have shown considerable promise in this context. We herein review noteworthy published data involving the use of additional lines of the therapy after failure of standard frontline therapies in patients with aGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.